Men had a higher mortality rate than women (33.3% and 6.7%, p = 0.05), the mortality rate in the group of patients who had received 2 doses of the vaccine was lower than that of the group that did not receive the full dose (10% vs 36%), P = 0.04), the mortality rate was higher in the dyspnea group than in the non-dyspnea group (38.5% and 5.3%, p = 0.01) Conclusions: Vaccines are valuable in significantly reducing the risk of dying from COVID in cancer patients.